. 2023 Feb 7:1–15. Online ahead of print. doi: 10.1038/s41577-023-00837-1

Table 2.

Potential therapeutic indications of TREM-based therapies

TREM target	Goal	Indications	Therapeutics	ClinicalTrials.gov ID
TREM1	Activation	Tumours^a, synergy with immune checkpoint therapy^a, liver disease, stroke, cardiovascular disease	Agonistic TREM1 antibodies, small TREM1 agonists	NCT04682431
TREM1	Inhibition	Sepsis^a, tumours, liver inflammation	Ligand-trapping peptide (LR12), TREM1-Fc decoy, signalling-blocking peptide (GF9)	NCT04429334
TREML1	Inhibition	Sepsis	Ligand-trapping peptide, blocking antibodies	–
TREM2	Activation	Alzheimer disease^a, metabolic disease	Agonistic antibodies, small molecules	NCT04592874
TREM2	Inhibition	Tumours^a, synergy with immune checkpoint therapy^a	TREM2-blocking antibodies, small-molecule TREM2 inhibitors, antibodies depleting TREM2⁺ tumour-associated macrophages	NCT04691375

^aIndications in which triggering receptor expressed on myeloid cells (TREM)-based therapeutics are currently being tested in clinical trials.